Target intelligence / Profile preview

Plasma membrane of Leishmania species (None)

Target
None
Molecular classification
Other (includes lipids, proteins, carbohydrate structures such as lipophosphoglycan, transporters, channels, and glycoproteins)
01

Overview

The Leishmania membrane is a dynamic, multi-component structure vital for parasite survival and pathogenicity. It consists of a lipid bilayer embedded with proteins, glycoproteins, and carbohydrate moieties such as lipophosphoglycan, which play key roles in host immune modulation and parasite protection. The membrane includes the specialized flagellar pocket, the only site of endo/exocytosis in the parasite, and interfaces with host cells through the parasitophorous vacuole membrane following infection. Surface molecules contribute to immune evasion and signal transduction, with variability across species and lifecycle stages. While specific membrane proteins—such as transporters, channels, and protein coats—can be drug targets or biomarkers, the generic "membrane of Leishmania species" is not a validated, precise therapeutic target, and its use should be supplanted by more targeted molecular definitions.

Other names
Leishmania membraneLeishmania surface membraneLeishmania plasma membraneLeishmania cell membranemembrane of Leishmania parasites
02

Mechanism of action

For drugs acting at the membrane, mechanisms include binding ergosterol-related sterols (amphotericin B), enhancing membrane permeability, and disrupting membrane function

03

Biological functions

Protection and compartmentalizationNutrient acquisition via specific transportersImmune evasion (via surface molecules like lipophosphoglycan)Attachment and motility (by membrane-associated flagellum)Host-parasite interactions (membrane at interface with host cells, e.g., parasitophorous vacuole membrane)
04

Disease associations

Infection (specifically leishmaniasis—cutaneous and visceral forms)Immune evasionHost cell modulation
05

Safety considerations

Nonspecific membrane targeting may risk toxicity to host cells; need for selectivity and specificityChallenges include the parasite's immune evasion tactics and adaptation of membrane composition
06

Interacting drugs

None specifically target "Leishmania membrane" as an entity, but antileishmanial drugs (e.g., amphotericin B, miltefosine) disrupt membrane integrity or membrane-associated processes
07

Biomarkers

Surface lipophosphoglycan variants (for species or lifecycle stage identification)No direct, broad membrane biomarkers

Beyond the preview

Go deeper on Plasma membrane of Leishmania species (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasma membrane of Leishmania species (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call